## A CLASSIFICATION OF SUBJECT MATTER IPC 7 C07C279/18 A61K31/155 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

 $\begin{array}{ccc} \text{Minimum documentation searched} & \text{(classification system followed by classification symbols)} \\ IPC & 7 & C07C & A61K \end{array}$ 

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

	ata base consulted during the international search (name of da		)
EPO-In	ternal, WPI Data, PAJ, MEDLINE,	BIOSIS, EMBASE	
	Space of the second		. * *
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the	ne relevant passages	Relevant to claim No.
P,X	WO 02/074756 A (PENTAPHARM AG HUGO (CH)) 26 September 2002 claims 1,12-15	;ZIEGLER (2002-09-26)	1,2,4-6, 8-16
X	STURZEBECHER J ET AL: "3-Amidinophenylalanine-based of Urokinase" BIOORGANIC & MEDICINAL CHEMISTOXFORD, GB, vol. 9, no. 21, 1 November 1999 (1999-11-01), 3147-3152, XP004181024 ISSN: 0960-894X page 3148, paragraph 1 tables 1,2 page 3147, paragraph 1 * Seite 3148, Formel 2 *	TRY LETTERS,	1-6, 13-16
X Furth	er documents are listed in the continuation of box C.	Patent family members are listed i	n annex.
•	egories of cited documents :	"T later document published after the inter or priority date and not in conflict with cited to understand the principle or the	the application but
"E" earlier de filing da "L" documer	ered to be of particular relevance ocument but published on or after the international site in which may throw doubts on priority claim(s) or s cited to establish the publication date of another	invention "X" document of particular relevance; the cannot be considered novel or cannot inventive step when the document	laimed invention be considered to turnent is taken alone
citation "O" document other m	or other special reason (as specified) nt referring to an oral disclosure, use, exhibition or	"Y" document of particular relevance; the ci cannot be considered to involve an inv document is combined with one or mo ments, such combination being obviou in the art.	rentive step when the re other such docu-
later tha	an the priority date claimed	"&" document member of the same patent f	
Date of the a	ctual completion of the international search	Date of mailing of the international sear	rch repart
29	October 2003	0.9	1. 01 2004
Name and m	ailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Beranová, P	
m PCT/ISA/21	10 (second shee!) (July 1992)	* * * * * * * * * * * * * * * * * * * *	



·Inter onai	A	on No
PCT/EP	03/	05918

Coto	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.
Category °	Citation of document, with indication, where appropriate, of the relevant passages	nelevani io ciami No.
X	MAGDOLEN V ET AL: "Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator."  ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. UNITED STATES 2000,	1,4-6, 11,13-16
	vol. 477, 2000, pages 331-341, XP008021329 ISSN: 0065-2598 table 2 * Seite 337, letzter Absatz bis Seite 338,	
•	erster Absatz *	
Υ	WO 00/04954 A (STUERZEBECHER JOERG ; LUTZ VERENA (DE); MAGDOLEN VIKTOR (DE); WILHE) 3 February 2000 (2000-02-03) claims 1,6,7	1-6, 11-16
Y	HEECHUNG YANG ET AL: "SELECTIVE INHIBITION OF UROKINASE BY SUBSTITUTED PHENYLGUANIDINES: QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP ANALYSES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 33, no. 11, 1990, pages 2956-2961, XP002059264 ISSN: 0022-2623 table 1 page 2956, right-hand column, paragraph 3	1-6, 11-16
Y	DE 199 40 389 A (WILEX BIOTECHNOLOGY GMBH) 1 March 2001 (2001-03-01) claim 9 * Seite 8, Verbindungen ST296 und ST 298 *	1-6, 11-16
Y	DE 100 29 014 A (UNIV SCHILLER JENA) 20 December 2001 (2001-12-20) claims 1,3	1-6, 11-16
Y	SPERL S ET AL:  "(4-Aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 10, 9 May 2000 (2000-05-09), pages 5113-5118, XP002169711 ISSN: 0027-8424 page 5113; table 1 page 5112, right-hand column, paragraph 2	1-6, 11-16
Υ	WO 01/070204 A (MAX PLANCK GESELLSCHAFT;STUERZEBECHER JOERG (DE); JACOB UWE (DE);) 27 September 2001 (2001-09-27) table 1	1-6, 11-16
	-/	



International	4)	ation No
PC T/EP	03,	/05918

ategory *	tion) DÖCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
-	NIENABER VICKI ET AL: "Re-engineering of	
	human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite."  JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 10, 10 March 2000 (2000-03-10), pages	
	7239-7248, XP002253397 ISSN: 0021-9258 page 7247, left-hand column, paragraph 2	·
٠		·
-		
		,
		·
		. ,
	;	
,		•



International application No.

PCT/EP 03/05918

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This inte	rnational search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
t	Although claim 13 relates to a method for treatment of the human or animal body, the search was carried out and was based on the stated effects of the compound or composition.
2. <b>X</b>	Claims Nos.:  7 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
	see FURTHER INFORMATION sheet PCT/ISA/210 x
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)
This Int	emational Searching Authority found multiple inventions in this international application, as follows:
	see FURTHER INFORMATION sheet
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. X	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
	1-4 (in part), 5, 6, 8-13 (in part), 14-16
Remar	k on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)



International application No. PCT/EP 03/05918

## Continuation of Box I, 2

## Claim 7

The current claims 1-6, 8-13, 14 and 16 relate to a disproportionately large number of possible compounds ("R6 are any residues", "aryl", "(substituted) heteroaryl (residue)", "R6 is the residue of an amino acid, a peptide or a polypeptide", "methylene groups are substituted", "piperidyl group which is substituted", "aromatic or cycloaliphatic ring", "alkyl residue", "substituted cycloalkyl residue", "aralkyl residue", "O aryl", "O-heteroaryl", "cycloaliphatic ring which is substituted", "heterocycloaliphatic residue", "substituted phenyl group") of which only a small portion are supported by the description (PCT Article 6) and can be regarded as having been disclosed in the application (PCT Article 5). In the present case the claims lack the proper support and the application lacks the requisite disclosure to such an extent that it appears impossible to carry out a meaningful search covering the entire range of protection sought. Therefore, the search was directed to the parts of the claims that appear to be supported and disclosed in the above sense, that is, the compounds as defined in the embodiments. including closely related homologous compounds.

The applicant is advised that claims relating to inventions in respect of which no international search report has been established normally need not be the subject of an international preliminary examination (PCT Rule 66.1(e)). In its capacity as International Preliminary Examining Authority the EPO generally will not carry out a preliminary examination for subjects that have not been searched. This also applies to cases where the claims were amended after receipt of the international search report (PCT Article 19) or where the applicant submits new claims in the course of the procedure under PCT Chapter II. After entry into the regional phase before the EPO, however, an additional search can be carried out in the course of the examination (cf. EPO Guidelines, Part C, VI, 8.5) if the deficiencies that led to the declaration under PCT Article 17(2) have been remedied.



International application No.

PCT/EP 03/05918

The International Searching Authority has determined that this international application contains more than one invention or group of inventions, namely:

1. claims 1-4 (in part), 5, 6, 8-13 (in part), 14-16

use of the urokinase inhibitors of formula I for treating tumours;

2. claims 1-4 (in part), 7, 8-13 (in part)

use of the urokinase inhibitors of formula I for treating pemphigus vulgaris.

Form PCT/ISA/210



Interrutional Application No PC 17EP 03/05918

					·
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 02074756	A	26-09-2002	WO EP	02074756 A2 1373234 A2	26-09-2002 02-01-2004
WO 0004954	A	<b>03-02-200</b> 0	AT AU AU BR CA DE WO EP ES JP US US	230599 T 754958 B2 5161599 A 9912327 A 2338073 A1 59903981 D1 0004954 A2 1264828 A1 1098651 A2 2189455 T3 2002521348 T 2003013723 A1 6624169 B1	15-01-2003 28-11-2002 14-02-2000 02-05-2001 03-02-2000 13-02-2000 11-12-2002 16-05-2001 01-07-2003 16-07-2002 16-01-2003 23-09-2003
DE 19940389	A	01-03-2001	DE AU WO EP	19940389 A1 7903400 A 0114324 A1 1206447 A1	01-03-2001 19-03-2001 01-03-2001 22-05-2002
DE 10029014	A	20-12-2001	DE AU CA WO EP US	10029014 A1 8575001 A 2411981 A1 0196286 A2 1294742 A2 2003166576 A1	20-12-2001 24-12-2001 09-12-2002 20-12-2001 26-03-2003 04-09-2003
WO 0170204	A	27-09-2001	DE AU WO EP US	10013715 A1 6379101 A 0170204 A2 1267854 A2 2003100584 A1	27-09-2001 03-10-2001 27-09-2001 02-01-2003 29-05-2003